EN DE

Great Tree Pharmacy Co (6469) Fair Value & Analysis

Healthcare · TW · Market cap 11.8B TWD

GT Great Tree Pharmacy Co 6469 · TWO
Price70.70 TWD
Fair Value69.43 TWD
Upside-1.8%
Quality44/100
Watch Great Tree Pharmacy Co for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 3.0% net margin
Low debt · generates free cash flow
4.11% dividend yield
Mixed vs. peers (8/14)
Narrow moat 42/100
Evidence: High Range 50.99 TWD – 87.86 TWD Share as image

Fair value as of: Jul 23, 2026

From 26 valuation models · updated 18 days ago

Share price −9.4% over the past month.

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Our model range runs from 50.99 TWD (bear) to 87.86 TWD (bull), base 69.43 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 44/100 (below-average quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

275.01 TWD 34.83 TWD Fair Value 69.43 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 34.83 TWD – 275.01 TWD · fair‑value band 50.99 TWD – 87.86 TWD · the 70.70 TWD price screens above the 69.43 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Great Tree Pharmacy Co (6469) currently trades at 70.70 TWD, while our model-based Fair Value estimate is 69.43 TWD, implying the stock looks roughly 1.8% fairly valued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Great Tree Pharmacy Co generated revenue of 19.1B TWD at a net margin of 3.0%. Revenue grew 3.7% year over year. It earns a return on equity of 15.4%. Net debt stands at 684M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 50.99 TWD (bear case) to 87.86 TWD (bull case); at 70.70 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 52% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at -2%, 6469 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 88.58 TWD 160.04 TWD 304.49 TWD 80
Residual Income 26.56 TWD 33.05 TWD 69.30 TWD 76
Rev-Margin DCF 63.29 TWD 116.44 TWD 212.55 TWD 74
All 26 models by family
DCF Models
FCF DCF 93.83 TWD 144.49 TWD 305.82 TWD 38
Owner Earnings 121.02 TWD 268.39 TWD 577.77 TWD 31
5Y Revenue Exit 63.29 TWD 102.43 TWD 183.58 TWD 39
5Y EBITDA Exit 106.39 TWD 190.01 TWD 353.32 TWD 41
5Y P/E Exit 77.00 TWD 159.46 TWD 270.55 TWD 38
10Y Revenue Exit 71.12 TWD 140.62 TWD 184.63 TWD 36
10Y EBITDA Exit 104.37 TWD 232.58 TWD 465.67 TWD 37
10Y P/E Exit 82.98 TWD 169.88 TWD 315.29 TWD 35
Earnings-Based
Graham-Dodd 27.23 TWD 189.88 TWD 266.47 TWD 54
Lynch FV 69.09 TWD 98.70 TWD 128.31 TWD 50
PEG = 1.0 69.09 TWD 98.70 TWD 128.31 TWD 46
EPV 38.14 TWD 43.58 TWD 48.34 TWD 59
Dividend Discount
Gordon GGM 26.74 TWD 55.60 TWD 88.20 TWD 70
DDM Multi-Stage 26.74 TWD 46.88 TWD 58.35 TWD 61
Multiples
P/E Multiple 63.06 TWD 84.09 TWD 105.11 TWD 63
P/S Multiple 51.05 TWD 68.07 TWD 85.09 TWD 58
P/B Multiple 51.05 TWD 68.07 TWD 85.09 TWD 55
EV/EBIT 64.10 TWD 83.64 TWD 103.18 TWD 53
EV/EBITDA 107.66 TWD 141.71 TWD 175.77 TWD 54
EV/Revenue 47.32 TWD 65.25 TWD 83.18 TWD 43
Asset-Based
NCAV (Graham) 13.06 TWD 17.51 TWD 26.13 TWD 50
Growth DCF
Growth DCF 88.58 TWD 160.04 TWD 304.49 TWD 80
Rev-Margin DCF 63.29 TWD 116.44 TWD 212.55 TWD 74
Economic Profit
Residual Income 26.56 TWD 33.05 TWD 69.30 TWD 76
ROIC Compounder 47.49 TWD 69.27 TWD 83.87 TWD 72
Growth Earnings
Growth-Adj P/E 89.04 TWD 127.20 TWD 165.36 TWD 68

Widest divergence: DCF Models (159.46 TWD) versus Asset-Based (17.51 TWD). Highest evidence: Growth DCF (80).

Notify me when 6469 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 19.1B TWD
Revenue growth (YoY) +3.7%
Net margin 3.0%
Return on equity 15.4%
Free cash flow 787M TWD FY2025
P/E ratio 21.5
More key figures
Operating margin 2.7%
EPS (TTM) 3.66 TWD
Dividend yield 4.1%
EPS growth (YoY) -22.1%
Net debt 684M TWD FY2025

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 44/100

Of which business quality 47 · Market factors (momentum, volatility) 33

Profitability 59
Margins and returns on capital today
Quality Growth 42
Are margins and returns improving?
Cashflow 53
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 58
Disciplined investing over empire-building
Low Volatility 85
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Great Tree Pharmacy Co., Ltd. engages in medicines, health food, maternal and infant products, and cosmetics businesses in Taiwan, Mainland China, and Malaysia. It provides drug procurement services, as well as acts as an agent for various clinics, joint clinics, and community health centers.

Full company description

Great Tree Pharmacy Co., Ltd. engages in medicines, health food, maternal and infant products, and cosmetics businesses in Taiwan, Mainland China, and Malaysia. It provides drug procurement services, as well as acts as an agent for various clinics, joint clinics, and community health centers. The company is also involved in selling food and beverages, and daily necessities; cleaning supplies; wholesale and retail of cosmetics, and other goods; cargo sorting, packaging, and warehousing; retail sale of animal medicines and ornamental animals; fish and pet food retail; medical equipment and pet-related products; wholesale of precision instruments; development and retail business; biotechnology; investment business, and specific specialized zones businesses. In addition, it provides technical services; management consultants, residential and building properties; development, leasing, rental, and sales of real estate; property leasing; industrial plant development; biotechnology research and development; and other wholesale and retail business. The company was formerly known as Tianjin Pharmaceutical Co., Ltd. and changed its products to Great Tree Pharmacy Co., Ltd. The company was incorporated in 2001 and is based in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Great Tree Pharmacy Co reported revenue of 18.9B TWD in FY2025 versus 11.3B TWD in FY2021, a compound +13.8%/yr. Reported net income was 600M TWD in FY2025, compounding +10.2%/yr from FY2021.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
18.9B TWD
Latest YoY
+9.4%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+9.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.9%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+26.3%
Revenue +13.8%/yr
FY21 11.3B TWD
FY22 14.6B TWD
FY23 16.1B TWD
FY24 17.3B TWD
FY25 18.9B TWD
Net income +10.2%/yr
FY21 407M TWD
FY22 700M TWD
FY23 666M TWD
FY24 681M TWD
FY25 600M TWD
Character of growth · EPS growth decomposed (2012-2023) +21.7 % p.a.
Revenue per share +24.9 pp

of which total revenue +30.9 pp · buybacks/dilution −6.1 pp

EBIT margin −1.2 pp
Tax rate −0.3 pp
Residual (interest, one-offs) −1.7 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 6469: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Great Tree Pharmacy Co Fair Value". https://www.fairvalue-calculator.com/stock/6469

Peer Group

Pharmaceutical Retailers · 61 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 44 · Below median
Fair Value upside +4% · Above median
Return on equity (TTM) 15% · Top 25%
Return on assets 3% · Above median
Net margin (TTM) 3% · Above median
Operating margin (TTM) 3% · Above median
Revenue growth 4% · Above median
Dividend yield (TTM) 4.1% · Above median
Debt / equity 0.24× · Higher than median

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 21.5× · Pricier than median
P/B 3.01× · Pricier than 75% of peers
P/S (TTM) 0.62× · Pricier than median
P/FCF 0.5× · Cheaper than 75% of peers
EV/EBITDA 12.3× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 39 · sector 19
FUTURE 19 · sector 19
PAST 62 · sector 19
HEALTH 88 · sector 97
DIVIDEND 82 · sector 66

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$39.20 HK$33.28 -15%
Raia Drogasil S.A RADL3 R$18.20 R$15.58 -14%
Yifeng Pharmacy Chain Co 603939 ¥23.43 ¥29.07 +24%
DaShenLin Pharmaceutical Group 603233 ¥18.23 ¥23.86 +31%
Corporativo Fragua, S.A. FRAGUAB 463.00 MXN 821.18 MXN +77%
LBX Pharmacy Chain Joint Stock Company 603883 ¥12.74 ¥10.57 -17%
MedPlus Health Services Limited MEDPLUS ₹690.20 ₹379.25 -45%
Yixintang Pharmaceutical Group 002727 ¥11.46 ¥9.45 -18%
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.40 ¥10.05 -30%
Apotea AB APOTEA kr 74.75 kr 43.95 -41%

Compare Great Tree Pharmacy Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Great Tree Pharmacy Co (6469) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 69.43 TWD versus a price of 70.70 TWD, about −2% (fairly valued).
What is the fair value of 6469?
Our model-based fair value for Great Tree Pharmacy Co is 69.43 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 70.70 TWD.
What is the quality score of 6469?
Great Tree Pharmacy Co has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Great Tree Pharmacy Co (6469)?
Great Tree Pharmacy Co reported trailing-twelve-month revenue of about 19.1B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 6469?
The net profit margin of Great Tree Pharmacy Co is about 3.0%, meaning it keeps roughly 3.0% of revenue as net income. Based on the latest reported figures.
Does Great Tree Pharmacy Co pay a dividend?
Great Tree Pharmacy Co currently shows a dividend yield of about 4.11% relative to its recent price (as of Jul 23, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Great Tree Pharmacy Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.